5-Amino-1MQ: Uses, Benefits & Research

What is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule quinolinium compound — classified as a small molecule rather than a classical peptide — that inhibits the enzyme nicotinamide N-methyltransferase (NNMT). It has no amino acid sequence and is chemically distinct from peptides, though it is frequently combined with them in therapeutic stacks. With a molecular weight of just 158.2 Da and the molecular formula C10H10N2, it belongs to a different class of compounds.

The compound has generated interest due to preclinical research showing NNMT inhibition can improve metabolic markers in obese mice. However, the critical fact is that 5-Amino-1MQ has zero human studies — it has never been tested in a single human subject.

Mechanism of Action

NNMT is an enzyme that “consumes” NAD+ by methylating nicotinamide (a form of vitamin B3). Inhibiting NNMT preserves NAD+ levels, which theoretically improves metabolic function in fat cells. This is conceptually related to the same pathway targeted by NAD+ precursors like NMN and NR, but through a different approach: rather than providing more NAD+ building blocks, NNMT inhibition prevents NAD+ breakdown.

In preclinical models, this mechanism has been linked to:

• Reduced fat mass and weight gain in obese mice
• Elevated NAD+ levels in adipose tissue
• Improved glucose tolerance and insulin sensitivity
• Enhanced fat oxidation

Whether any of these effects translate to humans is completely unknown. No human pharmacodynamic studies have been conducted.

Clinical Evidence

Human Studies

There are zero human studies on 5-Amino-1MQ. This includes:

• 0 randomized controlled trials
• 0 observational studies
• 0 case reports
• 0 registered clinical trials
• 0 pharmacokinetic data
• 0 safety data

Any marketing material claiming “studies show” benefits in humans is misrepresenting preclinical animal data.

Preclinical Evidence

All evidence comes from mouse models:

Model	Finding	Limitation
Diet-induced obesity (mouse)	Reduced weight gain, improved metabolism	Species differences in metabolism
NNMT inhibition (mouse)	Elevated NAD+ in adipose tissue	No human confirmation
Fat mass (mouse)	Reduced fat mass	Metabolic compounds frequently fail in translation
Glucose tolerance (mouse)	Improved insulin sensitivity	No human dose-response data

Drug Interactions & Contraindications

No formal drug interaction studies exist. All interactions are theoretical based on proposed mechanism:

• NAD+ precursors (NMN, NR): Theoretical additive effect on NAD+ levels
• Sirtuin activators: May affect NAD+-dependent pathways
• Chemotherapy agents: May affect cell metabolism
• Diabetes medications: May affect glucose metabolism

Contraindicated in pregnancy/breastfeeding and active malignancy. No established safe human dose exists.

Safety & Side Effects

Human safety data does not exist. There is no Phase I safety study, no adverse event reporting, and no long-term safety data. Theoretical concerns include:

• Unknown toxicity at any dose
• NNMT has normal biological functions that may be disrupted
• Altering NAD+ metabolism may have broad unintended effects
• Small molecules frequently have off-target effects
• NAD+ metabolism intersects with cell growth pathways (theoretical cancer risk)

Any claims about safety are not supported by human evidence.

Honest Bottom Line

5-Amino-1MQ requires the most careful honesty of any compound in this series. It is a small molecule — classified differently from classical peptides — that has been adopted by the peptide marketplace without undergoing any of the standard pharmaceutical development pathway. It has zero human studies, no established safe dose, and a completely unknown safety profile.

The preclinical science is legitimate — NNMT inhibition is a real scientific target, and the mouse data showing metabolic improvements is valid within its context. But mice are not humans, metabolic compounds notoriously fail in translation, and the complete absence of any human data means we simply do not know if this works or is safe in people.

Anyone considering 5-Amino-1MQ should understand they would be taking a research chemical with zero human testing. This is fundamentally different from using peptides with even limited human data.